Skip to content

Aspen Launch Philippines Business

Aspen, Africa’s largest pharmaceutical manufacturer and the biggest listed pharmaceutical group in the health care sector of the Johannesburg Stock Exchange, through Aspen Pharmacare Australia, one of the leading pharmaceutical companies in Australia, aims to make high-quality branded medicine available to Filipino patients at affordable cost through the launch of its local subsidiary, Aspen Philippines.

Read More

Australian Packaging Covenant – Aspen Report

The Australian Packaging Covenant is a voluntary initiative by Government and Industry to reduce the environmental effects of packaging. It is designed to minimise the environmental impacts arising from the disposal of used packaging, conserve resources through better design and production processes and facilitate the re-use and recycling of used packaging materials.

Here you can view Aspen Australia’s plan and report.

Read More

UPDATE: Important Information regarding Di-gesic and Doloxene.

UPDATE: We wish to advise you that the Administrative Appeals Tribunal (AAT) has granted Aspen Australia’s application to stay the cancellation of products containing dextropropoxyphene (Di-Gesic and Doloxene) from the ARTG. This allows us the opportunity to have our appeal of the Therapeutic Goods Administration’s (TGA) decision to cancel the registrations heard by the AAT.

Read More

South China Morning Post Article

In a span of 11 years, Aspen Pharmacare Australia has become one of Australia’s leading pharmaceutical companies, developing a reputation for reliable, regulated and affordable medicines. Aspen-marketed brands account for one out of seven prescriptions written in the country.

Read More

Business Review Australia Article

Aspen Pharmacare Australia Expanding Global Business – from recent acquisition to expansion plans in Asia, Aspen Pharmacare Australia is ready to increase sales and markets.

Read More

Aspen to distribute Merck products

Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.

Read More
Scroll To Top